Source-grounded facts extracted from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Approval of Amendment to the 2020 Equity Incentive Plan at the 2026-06-03 meeting.
“Proposal 4: Approval of Amendment to the 2020 Equity Incentive Plan For Against Abstain Broker Non-Votes 114,865,820 20,469,132 1,896,112 65,778,311 The stockholders approved the amendment to the 2020 Plan”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Advisory Vote on Approval of Named Executive Officer Compensation at the 2026-06-03 meeting.
“Proposal 3: Advisory Vote on Approval of Named Executive Officer Compensation For Against Abstain Broker Non-Votes 114,050,930 21,239,989 1,940,145 65,778,311 The stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-06-03 meeting.
“Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 198,046,666 3,990,483 972,226 — The stockholders ratified the appointment of Ernst & Young LLP”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Election of Four Class III Directors at the 2026-06-03 meeting.
“Proposal 1: Election of Four Class III Directors Name of Director For Against Abstain Broker Non-Votes William Ericson 128,010,323 8,109,601 1,111,140 65,778,311 Kathy Ordoñez 130,522,400 5,673,816 1,034,848 65,778,311 Christopher M. Smith 131,731,235 4,069,337 1,430,492 65,778,311 Chris Gibson, Ph.D. 131,899,750 4,107,270 1,224,044 65,778,311 Christian O. Henry 129,999,918 5,924,115 1,307,031 65,778,311 John F. Milligan, Ph.D. 130,471,635 5,650,906 1,108,523 65,778,311 Each director nominee was duly elected”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported for its first fiscal quarter ended March 31, 2026 results: revenue $37.2, net income GAAP net loss for the first quarter of 2026 was $8.3 million, EPS GAAP net loss per share for the first quarter of 2026 was $0.03. Guidance reaffirmed.
“which has the potential to produce the largest and most diverse high-fidelity metagenomic dataset in the world." First quarter results: Q1 2026 Q1 2025 Revenue (in millions) $37.2 $37.2 Consumable revenue (in millions) $21.8 $20.1 Instrument revenue (in millions) $9.7 $11.0 Service and other revenue (in millions) $5.6 $6.0 Revio TM system placements 15 12”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. completed a disposition involving Illumina Cambridge Limited for $50.0 million in cash (closed 2026-01-30).
“On January 30, 2026, Pacific Biosciences of California, Inc. (the “Company”) completed the disposition of assets to Illumina Cambridge Limited (the “Buyer”) in accordance with the terms of an Asset Purchase Agreement, dated January 30, 2026 (the “Asset Purchase Agreement”), by and between the Company, the Buyer, and Illumina, Inc., solely for purposes of Section 8.16 of the Asset Purchase Agreement, pursuant to which, among other matters, the Buyer acquired certain intellectual property and other assets related to the Company’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies (the “Asset Sale”). As consideration for the Asset Sale, the Buyer paid the Company $50.0 million in cash and assumed certain liabilities (the “Purchase Price”).”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. announced a restructuring with charges of approximately $5 million in 2025.
“In connection with the plan, the Company estimates that it will incur approximately $5 million in 2025, consisting primarily of employee severance and benefit costs, which will be future cash expenditures.”
Christian Henry changed role as President and Chief Executive Officer at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..
“Christian Henry, the Company’s President and Chief Executive Officer, who has been serving also as the Company’s interim Chief Financial Officer and principal financial officer since December 6, 2024 will cease serving as interim Chief Financial Officer and principal financial officer upon commencement of Mr. Gibson’s employment but will continue serving as the Company’s President and Chief Executive officer.”
Jim R. Gibson was appointed as Chief Financial Officer at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..
“On March 24, 2025, Pacific Biosciences of California, Inc. (the “Company”) entered into an offer letter with Jim R. Gibson to serve as its Chief Financial Officer. Mr. Gibson will be appointed as the Company’s Chief Financial Officer and principal financial officer effective as of as his first date of employment, which is anticipated to be March 31, 2025”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. amended lease obligation with Menlo Park Portfolio II, LLC maturing April 30, 2034.
“(the “Company”) entered into a Third Amendment to Lease (the “Lease Amendment”) with Menlo Park Portfolio II, LLC (“Lessor”) to amend the Lease by and between Lessor and the Company, dated July 22, 2015, as amended by the First Amendment to Lease, dated December 23, 2016, and as further amended by the Second Amendment to Lease, dated December 30, 2019 (collectively, the “Lease”), relating to the Company’s corporate headquarters, research and development facilities, and manufacturing and distribution centers in Menlo Park, California.”
David Meline resigned as Director at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..
“David Meline, a member of the Board, notified the Company of his resignation from the Board, effective January 30, 2025”
Christopher M. Smith was appointed as Class III Director at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..
“appointed Christopher M. Smith to serve as a Class III director effective January 30, 2025”
Jeff Eidel departed as Chief Commercial Officer at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..
“On November 11, 2024, Pacific Biosciences of California, Inc. (the “Company”) notified Jeff Eidel that, in connection with an internal restructuring of the commercial organization, he would separate from his position as the Chief Commercial Officer on November 15, 2024.”
Susan Kim resigned as Chief Financial Officer at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..
“On November 5, 2024, Susan Kim notified the Company that she is voluntarily resigning as Chief Financial Officer of the Company effective on December 6, 2024, to accept a position at another organization.”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. announced a restructuring with charges of approximately $27 million affecting Pacific Biosciences of California, Inc..
“the Company expects to incur charges related to the Expense Reduction Plan to be approximately $27 million in fiscal 2024”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. updated its end of 2024 guidance (raised).
“Initiated activities to reduce annualized run-rate operating expenses and the Company expects to achieve above the high end of our previously provided range of non-GAAP reduction of $50 million to $75 million by the end of 2024 compared to our prior guidance of 5% operating expense growth.”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $78.2 million, compared to a net loss of $88.0 million for the first quarter, EPS Net loss per share for the first quarter of 2024 was $0.29, compared to net loss per share of $0.36 for the first quarte.
“Revenue of $38.8 million compared with $38.9 million in the prior-year period.”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported 2024 results: revenue $170 million to $200 million. Guidance lowered.
“PacBio now expects 2024 revenue to be in the range of $170 million to $200 million.”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended March 31, 2024 results: revenue $38.8 million. Guidance lowered.
“– PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024. Preliminary First Quarter Results · Preliminary revenue of $38.8 million, roughly flat compared with $38.9 million in the prior-year period. · Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period. · Consumables”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported fiscal year ended December 31, 2023 results: revenue Revenue of $200.5 million, net income Net loss for 2023 was $306.7 million, EPS Net loss per share for 2023 was $1.21.
“Fiscal year 2023 results • Revenue of $200.5 million, a 56% increase compared with $128.3 million in the prior-year period. • Instrument revenue of $120.5 million compared with $48.7 million in the prior-year period. • Consumables revenue of $63.4 million compared with $60.0 million in the prior-year period. • Service and other revenue of $16.6 million compared with $19.6 million in the prior-year period. Gross profit for 2023 was $52.8 million, representing an 8% increase compared with $49.0 million for 2022 and a gross margin of 26% in 2023 compared to 38% for 2022. Non-GAAP gross profit for 2023 was $54.9 million and represented a non-GAAP gross margin of 27% in 2023, compared to a non-GAAP gross profit of $49.8 million in 2022, which represented a non-GAAP gross margin of 39% (see accompanying tables for reconciliations of GAAP and non-GAAP measures). Operating expenses totaled $387.2 million for 2023, compared to $356.2 million for 2022. Non-GAAP operating expenses totaled $354.8”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported fourth fiscal quarter ended December 31, 2023 results: revenue Revenue of $58.4 million, net income Net loss for the fourth quarter of 2023 was $82.0 million, EPS Net loss per share for the fourth quarter of 2023 was $0.31.
“Fourth quarter results • Revenue of $58.4 million, a 113% increase compared with $27.4 million in the prior-year period. • Instrument revenue of $35.1 million compared with $6.1 million in the prior-year period. • Consumables revenue of $18.9 million compared with $16.7 million in the prior-year period. • Service and other revenue of $4.4 million compared with $4.6 million in the prior-year period. • Shipped 44 Revio TM sequencing systems in the fourth quarter of 2023, bringing the installed base as of December 31, 2023, to 173 systems. Gross profit for the fourth quarter of 2023 was $9.6 million, representing an 86% increase compared with $5.1 million for the fourth quarter of 2022 and a gross margin of 16% in the fourth quarter of 2023 compared to 19% for the fourth quarter of 2022. Non-GAAP gross profit for the fourth quarter of 2023 was $11.1 million and represented a non-GAAP gross margin of 19% in the fourth quarter of 2023, compared to a non-GAAP gross profit of $5.3 million in”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the full year ended December 31, 2023 results: revenue $200.5 million. Guidance reaffirmed.
“announced preliminary unaudited revenue for the fourth quarter 2023 and full year 2023 of $58.4 million and $200.5 million”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the fourth quarter ended December 31, 2023 results: revenue $58.4 million. Guidance reaffirmed.
“PacBio reported preliminary, unaudited revenue of approximately $58.4 million for its fourth quarter ended December 31, 2023.”
David Botstein resigned as Director at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..
“On December 7, 2023, David Botstein, a member of the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”), notified the Company of his resignation from the Board, effective immediately.”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended September 30, 2023 results: revenue $55.7 million, net income Net loss for the third quarter of 2023 was $66.9 million, EPS $0.26.
“PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023. Third quarter results • Revenue of $55.7 million”
David Meline was appointed as Class II Director at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..
“On October 13, 2023, the Board (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”) increased the size of the Board to ten directors and, upon the recommendation of its Corporate Governance and Nominating Committee, appointed David Meline to serve as a Class II director”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended June 30, 2023 results: revenue $47.6 million, net income $69.8 million, EPS $0.28.
“Revenue of $47.6 million, a 34% increase compared with $35.5 million in the prior-year period. • Recognized revenue on 47 sequencing systems in the second quarter, including 45 Revio systems and 2 Sequel IIe systems, compared to 36 Sequel II/IIe systems in the prior-year period. • Instrument revenue of $29.9 million compared with $15.6 million in the prior-year period. • Consumables revenue of $13.7 million compared with $14.6 million in the prior-year period. • Service and other revenue of $3.9 million compared with $5.3 million in the prior-year period. Gross profit for the second quarter of 2023 was $15.5 million, representing a 4% decrease compared with $16.2 million for the second quarter of 2022 and a gross margin of 33% in the second quarter of 2023 compared to 46% for the second quarter of 2022. Non-GAAP gross profit for the second quarter of 2023 was $15.7 million and represented a non-GAAP gross margin of 33% in the second quarter of 2023, compared to a non-GAAP gross profit”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. incurred convertible notes of $441 million in aggregate principal amount with Chimera Investment LLC at 1.375% per annum maturing December 15, 2030.
“On June 30, 2023, Pacific Biosciences of California, Inc. (the “Company”) consummated the previously announced privately negotiated exchange with Chimera Investment LLC (“Chimera”), a holder of its outstanding 1.50% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which the Company issued $441 million in aggregate principal amount of the Company’s 1.375% Convertible Senior Notes due 2030 (the “New Notes”) in exchange for $441 million principal amount of the 2028 Notes (the “Exchange Transaction”),”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. entered into 1.375% Convertible Senior Notes due 2030 Indenture with U.S. Bank Trust Company, National Association valued at $441,000,000 aggregate principal amount of 1.375% Convertible Senior Notes due 2030 (effective 2023-06-30).
“On June 30, 2023, Pacific Biosciences of California, Inc. (the "Company") consummated the previously announced privately negotiated exchange with Chimera Investment LLC ("Chimera"), a holder of its outstanding 1.50% Convertible Senior Notes due 2028 (the "2028 Notes"), pursuant to which the Company issued $441 million in aggregate principal amount of the Company's 1.375% Convertible Senior Notes due 2030 (the "New Notes") in exchange for $441 million principal amount of the 2028 Notes (the "Exchange Transaction"), pursuant to exemptions from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder.”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders rejected Advisory Vote to Approve the Retention of the Classified Structure of the Corporation's Board at the 2023-05-24 meeting.
“Proposal 5: Advisory Vote to Approve the Retention of the Classified Structure of the Corporation’s Board For Against Abstain Broker Non-Votes 32,282,459 136,324,990 24,251,959 26,806,676”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Advisory Vote to Approve the Frequency of Future Advisory Votes on Named Executive Officer Compensation at the 2023-05-24 meeting.
“Proposal 4: Advisory Vote to Approve the Frequency of Future Advisory Votes on Named Executive Officer Compensation Every 1 Year Every 2 Years Every 3 Years Abstain Broker Non-Votes 134,152,334 238,320 58,328,847 139,910 26,806,673”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2023-05-24 meeting.
“Proposal 3: Advisory Vote to Approve Named Executive Officer Compensation. For Against Abstain Broker Non-Votes 178,087,666 14,553,090 218,655 26,806,673”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-05-24 meeting.
“Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 218,312,891 622,576 730,617 -”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Election of Three Class I Directors at the 2023-05-24 meeting.
“Proposal 1: Election of Three Class I Directors Name of Director For Against Abstain Broker Non-Votes Christian O. Henry 189,711,865 3,089,347 58,199 26,806,673 John F. Milligan, Ph.D. 190,066,819 2,674,761 117,831 26,806,673 Lucy Shapiro, Ph.D. 178,044,672 14,703,637 111,102 26,806,673”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended March 31, 2023 results: revenue $38.9 million, net income Net loss for the first quarter of 2023 was $88.0 million, EPS Net loss per share for the first quarter of 2023 was $0.36.
“Quarter 2023 Menlo Park, Calif. – May 2, 2023 – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2023. First quarter results • Revenue of $38.9 million, a 17% increase compared with $33.2 million in the prior year period. • Shipped 38 sequencing systems in the first quarter, including 32 Revio systems and 6 Sequel IIe systems. •”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported financial results for fourth fiscal quarter and year ended December 31, 2022.
“On February 16, 2023, Pacific Biosciences of California, Inc. (the “Company”) announced its financial results for its fourth fiscal quarter and year ended December 31, 2022. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference.”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Cowen and Company, LLC, as representatives of the several underwriters named therein valued at approximately $189.2 million (effective 2023-01-24).
“On January 24, 2023, Pacific Biosciences of California, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Cowen and Company, LLC, as representatives of the several underwriters named therein”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported fourth quarter ended December 31, 2022 results: revenue approximately $27.3 million.
“PacBio reported unaudited preliminary revenue of approximately $27.3 million for its fourth quarter ended December 31, 2022.”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported third quarter ended September 30, 2022 results: revenue $32.3 million, net income $77.0 million, EPS $0.34.
“Menlo Park, Calif. – November 7, 2022 – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2022. Third quarter results · Revenue of $32.3 million, a 7% decrease compared with $34.9 million in the prior year period. · Instrument revenue of $11.4 million, compared with $15.9 million in the prior year period. · Consumables”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: Amended and restated Second Amended and Restated Bylaws to revise director nomination and stockholder proposal procedures, conform to DGCL, update provisions on directors/committees/officers, clarify forum selection, and make ministerial updates (effective 2022-11-03).
“On November 3, 2022, the Company’s board of directors, upon recommendation of the corporate governance and nominating committee, amended and restated the Company’s Second Amended and Restated Bylaws, effective immediately (the “Amended and Restated Bylaws”).”
Peter Fromen resigned as Chief Commercial Officer at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..
“On May 14, 2022, Peter Fromen, the Chief Commercial Officer of Pacific Biosciences of California, Inc. (the “Company”), notified the Company of his intention to resign, effective as of May 20, 2022, to pursue new opportunities.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.